Jump to content

Sutro Biopharma: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Nickbow (talk | contribs)
49 edits
No edit summary
Nickbow (talk | contribs)
49 edits
No edit summary
Line 10: Line 10:
|logo = Sutro Biopharma Inc logo.png}}
|logo = Sutro Biopharma Inc logo.png}}


'''Sutro Biopharma''' is a private [[biopharmaceutical]] company headquartered in [[South San Francisco]] that develops best-in-class [[antibody-drug conjugate]] and [[multi-specific antibody-based therapeutics]] for cancer therapy.<ref>{{Cite news | title: Sutro's profile on Biospace| url:http://www.biospace.com/company_profile.aspx?CompanyId=1008256}}</ref> Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.<ref>{{cite news| title= William J Newell named CEO of Sutro Biopharma|url=http://www.sutrobio.com/william-j-newell-named-chief-executive-officer-of-sutro-biopharma-former-ceo-daniel-s-gold-ph-d-becomes-president-and-chief-operating-officer-company-notes-name-change-from-fundamental-applied/}}</ref> Newell has over 15 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Ayxs Pharmaceuticals, Inc. Sutro’s CFO, Edward Albini, previously worked at Itero Biopharmaceuticals, Novacea, and Lynx Therapeutics. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, Glaxo Group Research, and Roche Research Centre. The company received $26M in Series D funding in December 2013.<ref>{{cite news | title=Big Biopharmas help fuel a $26M round for Sutro's immunotherapy work|url=http://www.fiercebiotech.com/story/big-biopharmas-help-fuel-26m-round-sutros-antibody-rd-work/2013-12-11}}</ref> The company’s investors include Alta Partners, Skyline Ventures, SV Life Sciences, Lilly Ventures, Amgen Ventures and Celgene.<ref>{{cite news | title=Sutro Investors|url=http://www.sutrobio.com/leadership/#investors}}</ref>
'''Sutro Biopharma''' is a private [[biopharmaceutical]] company headquartered in [[South San Francisco]] that develops best-in-class [[antibody-drug conjugate]] and multi-specific antibody-based therapeutics for cancer therapy.<ref>{{Cite news | title: Sutro's profile on Biospace| url:http://www.biospace.com/company_profile.aspx?CompanyId=1008256}}</ref> Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.<ref>{{cite news| title= William J Newell named CEO of Sutro Biopharma|url=http://www.sutrobio.com/william-j-newell-named-chief-executive-officer-of-sutro-biopharma-former-ceo-daniel-s-gold-ph-d-becomes-president-and-chief-operating-officer-company-notes-name-change-from-fundamental-applied/}}</ref> Newell has over 15 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Ayxs Pharmaceuticals, Inc. Sutro’s CFO, Edward Albini, previously worked at Itero Biopharmaceuticals, Novacea, and Lynx Therapeutics. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, Glaxo Group Research, and Roche Research Centre. The company received $26M in Series D funding in December 2013.<ref>{{cite news | title=Big Biopharmas help fuel a $26M round for Sutro's immunotherapy work|url=http://www.fiercebiotech.com/story/big-biopharmas-help-fuel-26m-round-sutros-antibody-rd-work/2013-12-11}}</ref> The company’s investors include Alta Partners, Skyline Ventures, SV Life Sciences, Lilly Ventures, Amgen Ventures and Celgene.<ref>{{cite news | title=Sutro Investors|url=http://www.sutrobio.com/leadership/#investors}}</ref>


==Technology==
==Technology==

Revision as of 22:57, 14 July 2015

{{Multiple issues|

Sutro Biopharma
Company typePrivate
IndustrieBiotechnology
Gegründet2003 Edit this on Wikidata
HauptsitzSouth San Francisco
Websitesutrobio.com

Sutro Biopharma is a private biopharmaceutical company headquartered in South San Francisco that develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy.[1] Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.[2] Newell has over 15 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Ayxs Pharmaceuticals, Inc. Sutro’s CFO, Edward Albini, previously worked at Itero Biopharmaceuticals, Novacea, and Lynx Therapeutics. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, Glaxo Group Research, and Roche Research Centre. The company received $26M in Series D funding in December 2013.[3] The company’s investors include Alta Partners, Skyline Ventures, SV Life Sciences, Lilly Ventures, Amgen Ventures and Celgene.[4]

Technologie

Sutro's Xpress CF™ and Xpress CF+™[5] technologies are based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology.[6] The platform allows the parallel expression of hundreds of protein variants, including those incorporating non-natural amino acids, in as little as two weeks.[7] Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates (ADCs).[8] Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014[9] and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.[10]

Collaborations

In 2012 Sutro formed a collaboration with Celgene worth over $500 million, if all programs are successful to design and develop ADCs and bispecific antibodies for two undisclosed targets as well as manufacture a proprietary Celgene antibody using the company’s technology platform.[11] The company has also formed a collaboration with Sanofi Pasteur for the development of undisclosed vaccine candidates.[12] and a multi-year collaboration with Pfizer for the research, development and commercialization of peptide-based therapeutics.[13] In 2014 Sutro entered into a collaboration with Memorial Sloan-Kettering Cancer Center to produce four different bispecific antibodies that are discovered by MSKCC for the treatment of neuroblastoma in children using Sutro's technology. The bispecific monoclonal antibodies will be directed against CD3 on T-cells and, as the second target, against the ganglioside GD2, which is expressed on the surface of human neuroblastoma cells, as well as in melanoma and osteosarcoma.[14] In May 2014, Sutro signed a License and Agreement with EnWave Corporation. The company licensed EnWave’s Radiant Energy Vacuum technology to dehydrate cell-free extracts, which will facilitate both storage and shipping of extract for use in development and commercialization of Sutro products.[15] Also in 2014, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion[16] . In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono[17] is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.

References

  1. ^ {{cite news}}: Empty citation (help)
  2. ^ "William J Newell named CEO of Sutro Biopharma".
  3. ^ "Big Biopharmas help fuel a $26M round for Sutro's immunotherapy work".
  4. ^ "Sutro Investors".
  5. ^ "About Sutro's technology".
  6. ^ "Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production—A New Approach for Shortening Protein Production Development Timelines".
  7. ^ "Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production—A New Approach for Shortening Protein Production Development Timelines".
  8. ^ "Sutro's ADC technology".
  9. ^ "best scientific innovations".
  10. ^ "Fierce Biotech's 2014 Fierce 15".
  11. ^ "Celgene wraps $500M deal to partner with Sutro on next-gen ADCs".
  12. ^ "Sanofi Pasteur, Sutro team up on vaccine candidates".
  13. ^ "Sutro Strikes Deal With Pfizer".
  14. ^ "Memorial Sloan-Kettering to Use Sutro Technology for Neuroblastoma Research".
  15. ^ "EnWave Signs Commercial License with Sutro Biopharma for powderREV® Technology".
  16. ^ "Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro".
  17. ^ "Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sutro_Biopharma&oldid=671472941"